Dr. Christopher Pinard

Clinician Scientist
Medical Oncologist
Medical Board Director
Oncology Department Chair


Dr. Pinard is a clinician scientist and medical oncologist at Lakeshore Animal Health Partners, an adjunct professor in the Department of Clinical Studies at the University of Guelph, and a research fellow at Sunnybrook Research Institute with an interest in comparative oncology. His research focus is on the development of computational platforms for clinical biomarkers in canine and feline cancers using novel artificial intelligence and machine learning methods that can be utilized in comparative research. He continues to bridge the use of technology, including photogrammetry, 3D modelling and augmented reality, to improve patient care in real-time for surgical and ultrasound-guided practices.

Dr. Pinard is a member of the Temerty Centre for AI Research and Education in Medicine (T-CAIREM), a member of the International Immuno-Oncology Biomarker Working Group and is an affiliated faculty with the Centre for Advancing Responsible & Ethical Artificial Intelligence (CARE-AI). He is a founding member of the Comparative Oncology Artificial Intelligence Working Group (COAIG). He has sat on the Morris Animal Foundation Osteosarcoma Scientific Advisory Board and is currently funded for active clinical research. In his time off, he enjoys relaxing with his family at the cottage and cooking in the kitchen.

Board Certification: Diplomate, ACVIM (Oncology)


  • Bachelor of Science Honours (BScH), University of Guelph, Guelph ON (2008-2012)
  • Doctor of Veterinary Medicine (DVM), Ontario Veterinary College, Guelph ON (2012-2016)
  • Rotating Small Animal Internship, Veterinary Emergency Clinic, Toronto ON (2016-2017)
  • Oncology Clinical Trials Internship, Colorado State University CO (2017-2018)
  • Residency in Medical Oncology, Ontario Veterinary College, Guelph ON (2018-2021)
  • Doctor of Veterinary Science (DVSc), Ontario Veterinary College, Guelph ON (2018-2021)
  • Board-Certified Diplomate of the American College of Veterinary Internal Medicine in Oncology (ACVIM) (2021)

Recent Publications

  1. Pinard CJ on behalf of the International Immuno-Oncology Biomarker Working Group; Lagree, A, Lu FI, Klein J, Oblak ML, Salgado R, Cardenas JC, Brunetti B, Muscatello LV, Sarli G, Foschini MP, Hardas A, Castillo SP, AbdulJabbar K, Yuan Y, Moore DA, Tran WT. (2022). Comparative Evaluation of Tumor-Infiltrating Lymphocytes in Companion Animals: Immuno-Oncology as a Relevant Translational Model for Cancer Therapy. MDPI Cancers. http://dx.doi.org/https://doi.org/10.3390/cancers14205008
  2. Pinard CJ, Hocker SE, Poon A, Inkol J, Matsuyama A, Wood RD, Wood GA, Woods JP, Mutsaers AJ. (2022). Evaluation of PD-1 and PD-L1 expression on canine urothelial carcinoma cell lines.Vet Immunology and Immunopathology. http://dx.doi.org/10.1016/j.vetimm.2021.110367
  3. Pinard CJ, Stegelmeier AA, Bridle BW, Mutsaers AJ, Wood RD, Wood GA, Woods JP, Hocker SE. (2021). Evaluation of lymphocyte-specific programmed cell death protein 1 receptor expression and cytokines in blood and urine in canine urothelial carcinoma patients. Veterinary and Comparative Oncology. http://dx.doi.org/10.1111/vco.12788
  4. Laliberte SM, Poirier VJ, Pinard CJ, Hocker SE, Foster RA. (2021). A retrospective comparison of first and second opinion histopathology with patient outcomes in veterinary oncology cases (2011-2019). Veterinary and Comparative Oncology. http://dx.doi.org/10.1111/vco.12762
  5. Pinard C, Ludwig L, Egan R, Tatiersky L, Brooks M, Richardson D, Hocker SE, Bienzle D. (2021). Primary bone marrow T-cell lymphoma in a Golden Retriever. Veterinary Clinical Pathology. 50(1): 142-150. http://dx.doi.org/10.1111/vcp.13009
  6. Poirier VJ, Koh E, Darko J, Fleck A, Pinard C, Vail DM. (2021). Patterns of local residual disease and local failure after intensity modulated/image guided radiation therapy for sinonasal tumors in dogs. Journal of Veterinary Internal Medicine. 35(2): 1062-1072. http://dx.doi.org/10.1111/jvim.16076
  7. Hart E, Singh A, Thomson CB, Appleby R, Richardson D, Hocker SE, Bernard S, Pinard C. (2021). Outcomes after transperitoneal laparoscopic ureteronephrectomy for the treatment of primary renal neoplasia in seven dogs. Veterinary Surgery. http://dx.doi.org/10.1111/vsu.13675
  8. Pinard CJ, Hocker SE, Weishaar KM. (2020). Clinical outcome in 23 dogs with exocrine pancreatic carcinoma. Veterinary and Comparative Oncology. 19(1): 109-114. http://dx.doi.org/10.1111/vco.12645
  9. Pinard C, Cuq B, Gibson T, Brisson B, Plattner B, Lillie B, Bienzle D, Brouwer E, Gottstein B, and Peregrine A. (2019). Intolerance of albendazole therapy and failure to control hepatic alveolar echinococcosis in a dog in southern Ontario. Canadian Veterinary Journal. 60(10): 1099-1103.
  10. Séguin B, Pinard C, Lussier B, Williams D, Griffin L, Podell B, Mejia S, Timercan A, Petit Y, Brailovski V. (2019). Limb-sparing in dogs using patient- specific, three-dimensional printed endoprosthesis for distal radial osteosarcoma: a pilot study. Veterinary and Comparative Oncology. 18(1): 92-104. http://dx.doi.org/10.1111/vco.12515
  11. Hans EC, Pinard C, van Nimwegen SA, Kirpensteijn J, Singh A, MacEachern S, Naber S, Dudley RM. (2018). Effect of surgical site infection on survival after limb amputation in the curative intent treatment of canine appendicular osteosarcoma: a Veterinary Society of Surgical Oncology retrospective study. Veterinary Surgery. 47(8): E88-E96. http://dx.doi.org/10.1111/